-+ 0.00%
-+ 0.00%
-+ 0.00%

TransCode Therapeutics Reports Initial Dosing In Fourth Cohort Of Phase 1 Clinical Trial With TTX-MC138

Benzinga·03/27/2025 20:42:49
Listen to the news
  • First patient in Cohort four has been treated with TTX-MC138
  • Ten patients have been treated with TTX-MC138 at escalating dose levels
  • Additional patients being evaluated for eligibility for expanded enrollment
    • No significant safety or dose limiting toxicities have been reported